A Registry for People With Lung Cancer
Pulmonary Segmentectomy for Lung Cancer: A Real-World International Registry-TSOG 108
1 other identifier
observational
600
2 countries
15
Brief Summary
Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2024
Longer than P75 for all trials
15 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 15, 2024
CompletedFirst Submitted
Initial submission to the registry
May 16, 2024
CompletedFirst Posted
Study publicly available on registry
May 22, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 15, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 15, 2029
February 20, 2026
February 1, 2026
5 years
May 16, 2024
February 18, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Determine 3-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer.
DFS is measured from the date of surgery to the date of recurrence or death
3 years
Determine 5-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer.
DFS is measured from the date of surgery to the date of recurrence or death
5 years
Study Arms (1)
Participants with Lung Cancer
Participants undergoing planned pulmonary segmentectomy for primary lung cancer
Interventions
Participants-reported outcomes will be collected using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS is a web-based platform developed by the National Institutes of Health. Scoring is standardized on a scale from 0 to 100, with a population mean of 50 and standard deviation of 10 units. High scores mean more of the concept being measured. This study will use PROMIS surveys assessing three domains: physical function (PROMIS bank version 2.0), pain interference (PROMIS bank version 1.1), and dyspnea severity (PROMIS bank version 1.0)
Eligibility Criteria
All study subjects will be recruited from their respective clinics (i.e., Thoracic Surgery, Pulmonary, Survivorship, etc.) at participating sites. Potential research subjects will be identified by a member of the patient's treatment team, the protocol investigator, or research team by screening patients' medical records. If eligible, the study will be discussed with each patient.
You may qualify if:
- Age ≥18 years
- Clinical Stage I with suspected NSCLC, classified preoperatively based on the AJCC TNM staging manual, 9th edition o Note: Tissue diagnosis of NSCLC is not required before enrollment. A pathologic diagnosis of NSCLC may be confirmed preoperatively with biopsy, intraoperatively with frozen section, or postoperatively on final pathology
You may not qualify if:
- Actively receiving lung cancer treatment or a history of lung cancer in the previous 5 years
- History of chemotherapy or radiation therapy for a previous lung cancer
- Synchronous secondary cancer in the lung or elsewhere in the body at the time of surgery
- Carcinoid tumors
- History of other malignancies within the past 3 years, with the exception of non-melanoma skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix
- Actively receiving treatment for other malignancies
- Cases of lobectomy in conjunction with segmentectomy from another lobe and ≥2 segmentectomies from different lobes either en bloc or separate will be excluded from the primary analysis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (15)
Rush University Medical Center (Data collection only)
Chicago, Illinois, 606012, United States
Endeavor Health
Evanston, Illinois, 60201, United States
University of Michigan (Data Collection Only)
Ann Arbor, Michigan, 48109, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, 10604, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, 11553, United States
Thomas Jefferson University Hospital (Data Collection Only)
Philadelphia, Pennsylvania, 19107, United States
ALLEGHENY HEALTH NETWORK (Data Collection Only)
Pittsburgh, Pennsylvania, 15212, United States
MD Anderson Cancer Center (Data Collection Only)
Houston, Texas, 77030, United States
University Health Network (Data Collection Only)
Toronto, Ontario, M5G 2C4, Canada
Centre Hospitalier de l'Université de Montreal (Data Collection Only)
Montreal, Quebec, H2L 4M1, Canada
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
David Jones, MD
Memorial Sloan Kettering Cancer Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 16, 2024
First Posted
May 22, 2024
Study Start
May 15, 2024
Primary Completion (Estimated)
May 15, 2029
Study Completion (Estimated)
May 15, 2029
Last Updated
February 20, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will share
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.